Cargando…
B7–H3 as a Prognostic Biomarker and Therapeutic Target in Pediatric central nervous system Tumors
B7–H3 (CD276), a member of the B7 superfamily, is an important factor in downregulating immune responses against tumors. It is also aberrantly expressed in many human malignancies. Beyond immune regulatory roles, its overexpression has been linked to invasive metastatic potential and poor prognosis...
Autores principales: | Maachani, Uday B., Tosi, Umberto, Pisapia, David J., Mukherjee, Sushmita, Marnell, Christopher S., Voronina, Julia, Martinez, Daniel, Santi, Mariarita, Dahmane, Nadia, Zhou, Zhiping, Hawkins, Cynthia, Souweidane, Mark M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938869/ https://www.ncbi.nlm.nih.gov/pubmed/31887631 http://dx.doi.org/10.1016/j.tranon.2019.11.006 |
Ejemplares similares
-
Advances in Molecular Imaging of Locally Delivered Targeted Therapeutics for Central Nervous System Tumors
por: Tosi, Umberto, et al.
Publicado: (2017) -
PET, image-guided HDAC inhibition of pediatric diffuse midline glioma improves survival in murine models
por: Tosi, Umberto, et al.
Publicado: (2020) -
Utility of multimodality molecular profiling for pediatric patients with central nervous system tumors
por: Rajappa, Prajwal, et al.
Publicado: (2022) -
Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy
por: Chang, Raymond, et al.
Publicado: (2019) -
Central nervous system tuberculoma mimicking a brain tumor: A case report
por: McMahon, Pierce, et al.
Publicado: (2023)